Fosamprenavir: Advancing HIV protease inhibitor treatment options

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 9, 2004, Pages 1995-2005

  Becker, Stephen ^a,b   Thornton, Lorna ^a  

^a Pacific Horizon Medical Group   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amprenavir; Fosamprenavir; HIV; HIV protease inhibitor

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; ATORVASTATIN; CLARITHROMYCIN; CYTOCHROME P450 3A4; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETHINYLESTRADIOL PLUS NORETHISTERONE; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LAMIVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; METHADONE; MEVINOLIN; MIDAZOLAM; NELFINAVIR; PIMOZIDE; PRODRUG; PROTEINASE; PROTEINASE INHIBITOR; RIFABUTIN; RITONAVIR; SIMVASTATIN; TRIAZOLAM; UNINDEXED DRUG; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; FOOD DRUG INTERACTION; GENE MUTATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MEDICAL DECISION MAKING; NAUSEA AND VOMITING; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; VIRUS INHIBITION;

ANTI-HIV AGENTS; CARBAMATES; CLINICAL TRIALS, PHASE III; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PHOSPHORIC ACID ESTERS; PRODRUGS; SULFONAMIDES;

EID: 4544227361     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.9.1995     Document Type: Article

References (28)

1. TUNG RD, CHATURVEDI PR, BAKER C: Discovery of VX-175/GW433908, a novel, water soluble prodrug of amprenavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September (1999) (Abstract 916).
2. FURFINE ES, BAKER C, STUDENBERG S et al.: Preclinical development of GW433908/VX-175 the water soluble phosphate prodrug of amprenavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco CA, USA, September (1999) (Abstract 917).
3. SPALTENSTEIN A, BAKER C, GRAY-NUNEZ Y et al.: Highly polar, water soluble prodrugs of amprenavir: a new approach toward a more compact dosing regimen. 7th Conference on Retroviruses and Opportunistic Infections, January (2000) (Abstract 505).
4. FALCOZ C, JENKINS JM, BYE C et al.: Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J. Clin. Pharmacol. (2002) 42:887-898.
5. WOOD R, ARASTEH K, STELLBRINK HJ et al.: Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type-1 infected patients. Antimicrob. Agents Chemother. (2004) 48:116-123.
6. FALCOZ C, JENKINS JM, BYE C et al.: Single dose safety and pharmacokinetics of GW433908, a prodrug of amprenavir (141W94, APV), administered as an oral liquid formulation to healthy male subjects. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September (1999) (Abstract 918).
7. FALCOZ C, JENKINS JM, BYE C et al.: Food effect on single-dose safety and pharmacokinetics of GW433908, a prodrug of amprenavir (141W94, APV) administered as a tablet to healthy male study participants. 37th Annual Meeting of the Infectious Disease Society of America (Abstract 329).
8. GlaxoSmithKline: Lexiva® (fosmprenavir) package insert. GlaxoSmithKline, NC, USA (2003).
9. LAMOTTE C: Amprenavir (APV) plasma concentrations are dramatically increased by association to ritonavir (RTV) baby-doses in HIV-infected patients: possible combination with efavirenz. First International Workshop on Clinical Pharmacology of HIV Therapy (2000) (Abstract 2.7).
10. SADLER BM, PILIERO PJ, PRESTON SL, YU L, STEIN DS: Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple oral dosing. 7th Conference on Retroviruses and Opportunistic Infections, February (2000) (Abstract 77).
11. PEYTAVIN G, LAMOTTE C, DUVAL X et al.: Amprenavir (APV) plasma concentrations are dramatically decreased by association with ABT378/r in HIV-infected patients. 2nd International Workshop on Clinical Pharmacology of HIV Therapy (2001) (Abstract P1.14).
12. BASSO C, SOLAS C, QUINSON AM et al.: Pharmacokinetic interactions between lopinavir/r and amprenavir in salvage therapy. J. Acquir. Immune Defic. Syndr. (2002) 31(1):115-117.
13. MARZOLINI C, TIRONA RG, LEE W et al.: Unexpected complexity in nuclear receptor activation by HIV protease inhibitors and induction of CYP enzymes and transporters (135). Paper presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February 8-11 (2004).
14. BALDINI F, RIZZO MG, HOETELMANS R et al.: A prospective study of deep salvage therapy with lopinavir/r, amprenavir, and NRTIs: final 24- week data, pharmacokinetics, and association of drug levels/drug susceptibility with virologic response (423-W). Paper presented at 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 24-28 (2002).
15. DE WIT S, WAND H, LAW M et al.: Efficacy and tolerability of the combination of lopinavir/ritonavir (LPV/RTV) and amprenavir (APV) in patients with multiple protease inhibitors resistant HIV strains: results at week 24. Program and Abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, Greece, October 28-31 (2001) (Abstract p63).
16. KASHUBA ADM, TIERNEY C, DOWNEY GF, VERGIS EN et al.: Combining GW433908 (fosamprenavir; fosamprenavir) with lopinavir/ritonavir (LPV/R) in HIV-1 infected adults results in substantial reductions in amprenavir (APV and LPV concentrations: pharmacokinetic (PK) results from Adult ACTG Protocol A5143. Program and Abstracts of the 43rd Annual ICAAC Meeting, Chicago, Illinois, USA, September 14-17 (2003) (Abstract H-855a).
17. CORBETT AH, DAVIDSON L, PARK JJ et al.: Dose separation strategies to overcome the pharmacokinetic interaction of a triple protease inhibitor regimen containing fosamprenavir, lopinavir and ritonavir (611). Paper presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February 8-11 (2004).
18. WIRE MB, NADERER OJ, MASTERMAN AL et al.: The pharmacokinetic (PK) interaction between GW433908 (908) with lopinavir (LPV)/ritonavir (RTV) (APV10011 and APV10012). 11th Conference on Retroviruses and Opportunistic Infections, February (2004) (Abstract 612).
19. WIRE MB, PRESTON SL, BALLOW C et al.: An assessment of plasma amprenavir (APV) pharmacokinetics (PK) following administration of two GW433908 (908) and ritonavir (RTV) QD regimens in combination with efavirenz (EFV) in healthy adult subjects (APV10009). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, September (2002) (Abstract 1737).
20. BOFFITO M, DICKINSON L, HILL A et al.: Steady state pharmacokinetics of saquinavir hard gel/fosamprenavir 1000/700 plus 100 mg and 200 mg of ritonavir twice daily in HIV+ patients (608). Paper presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February 8-11 (2004).
21. GUFFANTI M, DE PASCALIS CR, SEMINARI E et al.: Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HI- positive patients. AIDS (2003) 17(18):2669-2671.
22. TISDALE M, MYERS R, RANDAL F et al.: Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies: a review. Clinical Drug Investigation (2000) 20:267-285.
23. ROSS L, PARKIN N, CHAPPEY C, TISDALE M, ELSTON R: HIV clinical isolates containing mutations representative of those selected after first line failure with unboosted GW433908 remain sensitive to other protease inhibitors. XII International HIV Drug Resistance Workshop (2003) (Abstract 19).
24. ELSTON R, MACMANUS S, YATES P et al.: Lack of resistance to boosted 908 confirmed through 48 weeks of therapy in naïve subjects. 2nd IAS Conference on HIV Pathogenesis and Treatment (2003) (Abstract 558).
25. RODRIGUEZ-FRENCH A, BOGHOSSIAN J, GRAY GE et al.: The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-Infected patients. J. AIDS (2004) 35:22-32.
26. GATHE JC Jr, IVE P, WOOD R: SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS (2004) 18(11):1529-1537.
27. DEJESUS E, GRINSZTEJN B, RODRIGUEZ C et al.: Efficacy and safety of atazanavir with ritonavir or saquinavir versus lopinavir/ritonavir in patients who have experienced virologic failure on multiple HAART regimens: 48 week results from BMS A124-045 (547). Paper presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February 8-11 (2004).
28. KEISER P, NASSAR N, YAZDANI B, ARMAS L, MORENO S: The use of observational databases to compare anti-retroviral effectiveness (559). Paper presented at 11th Conference on retroviruses and Opportunistic Infections, San Francisco, USA, February 8-11 (2004).